Market Cap 2.09B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.11
Volume 2,643,400
Avg Vol 5,909,618
Day's Range N/A - N/A
Shares Out 217.69M
Stochastic %K 78%
Beta 0.95
Analysts Strong Sell
Price Target $25.83

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
15 Crosby Drive, Bedford, United States
Dy2ski
Dy2ski Apr. 24 at 11:11 PM
$OCUL $SNY Sanofi just raised 2.5 Billion for "General Corporate Purposes...". https://markets.ft.com/data/announce/detail?dockey=1330-1001177896en-6MQ3QT8DO0ILMA3707MANN2U6Q
5 · Reply
rstrau
rstrau Apr. 24 at 9:52 PM
$OCUL, short interest as of 4/15 was 24.5 million shares, down by about 700,000 shares sinc3 3/31. But short interest on 1/30 was 11.5 million shares, so in 2 1/2 months shorts have increased by 14 million shares. On 1/30, the price closed at $9.12, so the shorts have piled on and the stock has gone up. While the shorts were selling, BlackRock was buying. I wonder who the smart money is here.
0 · Reply
Tmoney85285
Tmoney85285 Apr. 24 at 1:52 PM
$OCUL okay, this one was really funny. kudos- you have a future in graphic design, just not stocks!
0 · Reply
jolo11
jolo11 Apr. 24 at 12:43 PM
$OCUL upside is IMO, if trend continues in a positive direction with SOL, etc. this is an $80 stock on a BO. Downside is that will probably take 3 more years.
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Apr. 23 at 11:35 PM
$OCUL From Grok... SOL-1 alone provides high-quality, statistically robust, and clinically meaningful evidence of AXPAXLI’s effectiveness in wet AMD. It showed clear superiority on vision maintenance, durability, and anatomic control versus a relevant comparator, with a favorable safety profile. This meets or exceeds typical thresholds for “meaningful clinical evidence” in a pivotal Phase 3 setting and supports the company’s view of a strong regulatory path. Real-world confirmation and longer-term data will further strengthen this, but the SOL-1 results stand as compelling on their own. The only question that remains IMO is safety when re-dosed. This will be answered by the end of June when all of the Axpaxli arms in SOL-1 will have been re-dosed. Additional data from SOL-R will be available by the end of Dec.
1 · Reply
esu89
esu89 Apr. 23 at 1:30 AM
$OCUL at the investor update, I think we will get updates on the NPDR P3 trials and SOL-R and guidance that the NDA will be filed based solely on SOL-1 before the end of Q3. While it is possible that they could announce filing of the NDA that morning, I don’t think that is likely. I don’t see a partnership announcement anytime soon, nor do I want one. IMO, a partnership deal would signal to me that an acquisition is not happening anytime soon. Unless they can get $40 a share for the Company, I don’t want either an acquisition or partnership announced prior to wet AMD approval.
1 · Reply
Fairvalue10
Fairvalue10 Apr. 22 at 9:07 PM
$OCUL I’m sorry schultzeee but I don’t see why this date is important. Today’s primary trigger is the NDA filing, since that’s what they’ll be communicating on first, not what might happen in two months. Moreover, if you’re giving weight to the Sanofi rumors, the CEO change may have significantly altered the timing of any external growth move. Tomorrow you have Sanofi’s results, then on the 29th the new CEO takes office, right after the 29th is the critical window if something is going to happen. Honestly, Ocular is announcing a participation and you’re speculating on hypothetical events; RBC and Jefferies are far more significant conferences and nothing has ever been announced there by Ocular about nothing. Keep faith and stay long.
2 · Reply
Jjarnold44
Jjarnold44 Apr. 22 at 5:31 PM
$OCUL Giddy- up!
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Apr. 22 at 3:49 PM
$OCUL Very interesting timing of the Investor Conference.
2 · Reply
margold1969
margold1969 Apr. 22 at 3:23 PM
0 · Reply
Latest News on OCUL
Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Apr 22, 2026, 7:00 AM EDT - 3 days ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026


Ocular Therapeutix Transcript: Study update

Mar 2, 2026, 7:30 AM EST - 7 weeks ago

Ocular Therapeutix Transcript: Study update


Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 2 months ago

Ocular Therapeutix Transcript: Study result


Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025


Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 7 months ago

Ocular Therapeutix Transcript: Investor Day 2025


Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 9 months ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025


Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024


Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024


Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day


Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024


Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results


Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024


Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024


Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results


Ocular Therapeutix Earnings Call Transcript: Q3 2023

Nov 7, 2023, 4:30 PM EST - 2 years ago

Ocular Therapeutix Earnings Call Transcript: Q3 2023


Ocular Therapeutix Earnings Call Transcript: Q2 2023

Aug 7, 2023, 4:30 PM EDT - 2 years ago

Ocular Therapeutix Earnings Call Transcript: Q2 2023


Ocular Therapeutix Transcript: Study Update

Jun 12, 2023, 8:30 AM EDT - 3 years ago

Ocular Therapeutix Transcript: Study Update


Ocular Therapeutix Earnings Call Transcript: Q1 2023

May 8, 2023, 4:30 PM EDT - 3 years ago

Ocular Therapeutix Earnings Call Transcript: Q1 2023


Ocular Therapeutix Earnings Call Transcript: Q4 2022

Mar 6, 2023, 4:30 PM EST - 3 years ago

Ocular Therapeutix Earnings Call Transcript: Q4 2022


Ocular Therapeutix Transcript: Study Result

Feb 13, 2023, 8:30 AM EST - 3 years ago

Ocular Therapeutix Transcript: Study Result


Ocular Therapeutix Earnings Call Transcript: Q3 2022

Nov 7, 2022, 10:00 AM EST - 3 years ago

Ocular Therapeutix Earnings Call Transcript: Q3 2022


Ocular Therapeutix Transcript: Study Update

Sep 27, 2022, 8:00 AM EDT - 3 years ago

Ocular Therapeutix Transcript: Study Update


Ocular Therapeutix Earnings Call Transcript: Q2 2022

Aug 7, 2022, 11:59 PM EDT - 4 years ago

Ocular Therapeutix Earnings Call Transcript: Q2 2022


Ocular Therapeutix Earnings Call Transcript: Q1 2022

May 9, 2022, 5:28 AM EDT - 4 years ago

Ocular Therapeutix Earnings Call Transcript: Q1 2022


Ocular Therapeutix Earnings Call Transcript: Q4 2021

Feb 28, 2022, 4:41 AM EST - 4 years ago

Ocular Therapeutix Earnings Call Transcript: Q4 2021


Ocular Therapeutix Transcript: Study Result

Dec 6, 2021, 8:00 AM EST - 4 years ago

Ocular Therapeutix Transcript: Study Result


Ocular Therapeutix Earnings Call Transcript: Q3 2021

Nov 7, 2021, 7:00 PM EST - 4 years ago

Ocular Therapeutix Earnings Call Transcript: Q3 2021


Ocular Therapeutix Earnings Call Transcript: Q2 2021

Aug 9, 2021, 4:30 PM EDT - 5 years ago

Ocular Therapeutix Earnings Call Transcript: Q2 2021


Ocular Therapeutix Earnings Call Transcript: Q1 2021

May 5, 2021, 4:30 PM EDT - 5 years ago

Ocular Therapeutix Earnings Call Transcript: Q1 2021


Dy2ski
Dy2ski Apr. 24 at 11:11 PM
$OCUL $SNY Sanofi just raised 2.5 Billion for "General Corporate Purposes...". https://markets.ft.com/data/announce/detail?dockey=1330-1001177896en-6MQ3QT8DO0ILMA3707MANN2U6Q
5 · Reply
rstrau
rstrau Apr. 24 at 9:52 PM
$OCUL, short interest as of 4/15 was 24.5 million shares, down by about 700,000 shares sinc3 3/31. But short interest on 1/30 was 11.5 million shares, so in 2 1/2 months shorts have increased by 14 million shares. On 1/30, the price closed at $9.12, so the shorts have piled on and the stock has gone up. While the shorts were selling, BlackRock was buying. I wonder who the smart money is here.
0 · Reply
Tmoney85285
Tmoney85285 Apr. 24 at 1:52 PM
$OCUL okay, this one was really funny. kudos- you have a future in graphic design, just not stocks!
0 · Reply
jolo11
jolo11 Apr. 24 at 12:43 PM
$OCUL upside is IMO, if trend continues in a positive direction with SOL, etc. this is an $80 stock on a BO. Downside is that will probably take 3 more years.
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Apr. 23 at 11:35 PM
$OCUL From Grok... SOL-1 alone provides high-quality, statistically robust, and clinically meaningful evidence of AXPAXLI’s effectiveness in wet AMD. It showed clear superiority on vision maintenance, durability, and anatomic control versus a relevant comparator, with a favorable safety profile. This meets or exceeds typical thresholds for “meaningful clinical evidence” in a pivotal Phase 3 setting and supports the company’s view of a strong regulatory path. Real-world confirmation and longer-term data will further strengthen this, but the SOL-1 results stand as compelling on their own. The only question that remains IMO is safety when re-dosed. This will be answered by the end of June when all of the Axpaxli arms in SOL-1 will have been re-dosed. Additional data from SOL-R will be available by the end of Dec.
1 · Reply
esu89
esu89 Apr. 23 at 1:30 AM
$OCUL at the investor update, I think we will get updates on the NPDR P3 trials and SOL-R and guidance that the NDA will be filed based solely on SOL-1 before the end of Q3. While it is possible that they could announce filing of the NDA that morning, I don’t think that is likely. I don’t see a partnership announcement anytime soon, nor do I want one. IMO, a partnership deal would signal to me that an acquisition is not happening anytime soon. Unless they can get $40 a share for the Company, I don’t want either an acquisition or partnership announced prior to wet AMD approval.
1 · Reply
Fairvalue10
Fairvalue10 Apr. 22 at 9:07 PM
$OCUL I’m sorry schultzeee but I don’t see why this date is important. Today’s primary trigger is the NDA filing, since that’s what they’ll be communicating on first, not what might happen in two months. Moreover, if you’re giving weight to the Sanofi rumors, the CEO change may have significantly altered the timing of any external growth move. Tomorrow you have Sanofi’s results, then on the 29th the new CEO takes office, right after the 29th is the critical window if something is going to happen. Honestly, Ocular is announcing a participation and you’re speculating on hypothetical events; RBC and Jefferies are far more significant conferences and nothing has ever been announced there by Ocular about nothing. Keep faith and stay long.
2 · Reply
Jjarnold44
Jjarnold44 Apr. 22 at 5:31 PM
$OCUL Giddy- up!
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Apr. 22 at 3:49 PM
$OCUL Very interesting timing of the Investor Conference.
2 · Reply
margold1969
margold1969 Apr. 22 at 3:23 PM
0 · Reply
acdurham
acdurham Apr. 22 at 1:50 PM
$OCUL time for some FOMO
1 · Reply
MaxKlim
MaxKlim Apr. 22 at 1:34 PM
$OCUL 10$
0 · Reply
schultzeee
schultzeee Apr. 22 at 12:32 PM
$OCUL another investor day announced - this time it’s on June 17th. I wonder if they plan to have the NDA acceptance and the accompanying PDUFA date in hand by then. It doesn’t make much sense to have the investor day otherwise. If they do intend to have the NDA acceptance by that date it means they have already submitted the NDA package to the FDA.
5 · Reply
MaxKlim
MaxKlim Apr. 22 at 12:10 PM
0 · Reply
ProfitForever
ProfitForever Apr. 21 at 4:08 PM
$OCUL $10 plus next week imo!
2 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Apr. 21 at 3:52 PM
$OCUL This pull back is not a bad thing if it bounces here. Actually a BIG positive if tomorrow has a nice green candle. Wait and see.
0 · Reply
TBillyhatesmoney
TBillyhatesmoney Apr. 21 at 3:05 PM
$OCUL Here you go dumdum.
1 · Reply
Tmoney85285
Tmoney85285 Apr. 21 at 2:24 PM
$OCUL weird. i am right again! gave up all gains. keep making memes, idiot
4 · Reply
Quantumup
Quantumup Apr. 21 at 12:21 PM
TD Cowen🏁 $SRZN at a Buy rating. $OCUL $EYPT MRK REGN RHHBY FDMT KOD TD Cowen said in its initiation report: Surrozen is developing multifunctional antibodies that leverage Wnt activation for vascular retinopathies. Leadi candidate SZN-8141 combines Wnt agonism with VEGF antagonism and an IND is expected in H2:26. We estimate SZN-8141 addresses a $5B+ opportunity in wAMD and DME. We expect SRZN to create much L-T shareholder value as its pipeline advances. We are initiating with a Buy rating.
0 · Reply
Fairvalue10
Fairvalue10 Apr. 21 at 7:31 AM
$OCUL Why would you rather have Pravin tell them we're desperate and will take whatever offer comes in, even a lowball one ? He has to say that he will not sell cheap and he is ready to GIA
1 · Reply
TBillyhatesmoney
TBillyhatesmoney Apr. 20 at 4:04 PM
$OCUL Never fails
2 · Reply
Tmoney85285
Tmoney85285 Apr. 20 at 2:44 PM
$OCUL must be new here- don't be surprised when this gives alllllll its gains back from friday. heck, we are barely an hour in and a third of it is gone.
2 · Reply